Novozymes is a global biotechnology company headquartered in Bagsværd outside of Copenhagen, Denmark employing approximately 6,300 people by the end of 2013. The company has operations in a number of countries around the world, including China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Its B shares are listed on the NASDAQ OMX Nordic.The company’s focus is the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. As of 2013, the company holds an estimated 48% of the global enzyme market, making it the world’s largest producer of industrial enzymes. Wikipedia.
Sleep D.,Novozymes AS
Expert Opinion on Drug Delivery | Year: 2015
Introduction: Rapid clearance of drugs from the body results in short therapeutic half-life and is an integral property of many protein and peptide-based drugs. To maintain the desired therapeutic effect patients are required to administer higher doses more frequently, which is inconvenient and risks undesirable side effects. Drug delivery technologies aim to minimise the number of administrations and dose-related toxicity while maximising therapeutic efficacy. Areas covered: This review describes albumin's inherent biochemical and biophysical properties, which make it an attractive drug delivery platform and the developmental status of drugs that are associated, conjugated or genetically fused with albumin. Albumin interacts with a number of cell surface receptors including gp18, gp30, gp60, FcRn, cubilin and megalin. The importance of albumin's interaction with the FcRn receptor, the basis for albumin's long circulatory half-life, is described, as are engineered albumins with improved pharmacokinetics. Albumin naturally accumulates at tumours and sites of inflammation, a characteristic which can be augmented by the addition of targeting ligands. The development of albumin drug conjugates which reply upon this property is described. Expert opinion: Albumin's inherent biochemical and biophysical properties make it an ideal drug delivery platform. Recent advances in our understanding of albumin physiology and the improvement in albumin-based therapies strongly suggest that albumin-based therapies have a significant advantage over alternative technologies in terms of half-life, stability, versatility, safety and ease of manufacture. Given the importance of the albumin:FcRn interaction, the interpretation of the pharmacokinetic and pharmacodynamic profiles of albumin-based therapeutics with disturbed albumin:FcRn interaction may have to be reassessed. The FcRn receptor has additional functionality, especially in relation to immunology, antigen presentation and delivery of proteins across mucosal membranes, consequently albumin-based fusions and conjugates may have a future role in oral and pulmonary-based vaccines and drug delivery. © 2015 Informa UK, Ltd.
Roggen E.L.,Novozymes AS
Basic and Clinical Pharmacology and Toxicology | Year: 2014
Concerns, legislation and research needs have precipitated developments such as the mode of action concept, the Tox21 strategy, the concept of pathways of toxicity and the adverse outcome pathway framework. New technologies and paradigms are currently transforming these concepts into applicable animal-free toxicity testing systems. The adverse outcome pathway framework provides a structure for collecting, organizing and evaluating the available data that describe the compound and the events resulting in an adverse outcome at a biological level of organization. The current chapter intends to provide a non-exhaustive review of (i) our current understanding of the molecular mechanisms driven the key events of the mode of action for sensitization induction by chemicals, (ii) the tools that were developed on the basis of the available knowledge and (iii) the major gaps that need to be filled. © 2014 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
Agency: Cordis | Branch: FP7 | Program: CP | Phase: ENERGY.2012.3.2.3 | Award Amount: 34.53M | Year: 2014
The overall goal of COMETHA Project is the construction and operation of an integrated precommercial industrial facility for the production of 80,000 t/y of second generation bioethanol starting from lignocellulosic biomass (ethanol plant conversion yield: from 4.3 to 1) at Porto Marghera (VE, Italy). The plant will be the first in its kind at pre-commercial scale and will validate the innovative Biochemtex PROESA technology, already tested at pilot scale and in the next future through the operation of a 40,000 ton/y cellulosic ethanol Demo plant in Crescentino (start-up 2013). With the support of Venice Town and petrochemical companies, the realization of the Marghera 2G flagship will provide data for commercial scale-up and it serves as a vehicle for ongoing renewable technology improvement and bioethanol market deployment. The project will address the development of the sustainable biomass supply chain based on c.360,000 tonnes of lignocellulosic biomass per year derived from the Region of Veneto, such as dedicated perennial crops (Arundo donax) and agricultural residue (corn stover, the most suitable feedstock for bioethanol production in the considered geographical scenario). The COMETHA project will focus on demonstrating the second generation process steps in an integrated industrial scale biorefinery, including key innovative units (such as innovative proprietary pretreatment, SSCF with the use of novel high performance enzymes and modified MOs, high efficiency integrated distillation and dehydration system, valorisation of secondary streams and process integration). Moreover, a preliminary and detailed LCA of the bioethanol flagship plant for both Arundo donax and corn stover will demonstrate a substantial reduction in terms of GHG emissions of the 2G ethanol with respect to gasoline (82% and 86% respectively): this will certificate the respect of the scientific and technological quality criterion and the sustainability of Biochemtex PROESA technology.
Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2015-ETN | Award Amount: 4.07M | Year: 2016
The revolution of biotechnology has led to the creation of various types of therapeutic biologics with the potential to provide treatment for new chronic and malignant diseases. Though the potential advantages of biologics lay in their high specificity and potency combined with few side effects, their formulation still remains a large challenge to pharmaceutical scientists. This is in part due to the complex, not-well understood relationship between the physicochemical properties of proteins and formulation conditions required for protein stability. A comprehensive understanding of the molecular mechanisms behind protein stabilization and solubility would provide the formulation scientists with knowledge of the interplay between formulation and stability that in turn could potentially make formulation development faster, cheaper and less labour intensive than the currently used broad screening approach. Understanding the susceptibilities of formulations to protein aggregation and denaturation can reduce the response time to for instance product failure. Few universities in Europe have formulation of biologics as a scientific subject. Consequently, the pharmaceutical industry is forced to train scientists - a challenge for larger companies, and an insurmountable task for smaller companies. Scientists in the field of structural biology, biophysics, protein formulation and stability have formed a consortium to systematically map physicochemical properties of biologics, formulation conditions and protein stability. The main objective of the consortium is to provide a new generation of innovative and entrepreneurial early-stage researchers that will develop methodologies, tools and databases to guide the formulation of robust biologics. The consortium will not only provide an excellent platform to train a new generation of formulation scientists, but also establish avenues for designing new formulation strategies and thereby securing the leading edge of EU expertise.
Agency: Cordis | Branch: H2020 | Program: IA | Phase: BG-04-2014 | Award Amount: 7.40M | Year: 2015
INMARE stands for Industrial Applications of Marine Enzymes: Innovative screening and expression platforms to discover and use the functional protein diversity from the sea. It is a collaborative Innovation Action to streamline the pathways of discovery and industrial applications of new marine enzymes and bioactives for targeted production of fine chemicals, drugs and in environmental clean-up applications. The INMARE consortium will unify the multidisciplinary expertise and facilities of academic and industry partners. This will include integrating the following core activities: advanced technologies to access and sample unique marine biodiversity hot-spots; state-of-the art technologies for construction of metagenomic libraries; innovative enzyme screening assays and platforms; cutting-edge sequence annotation pipelines and bioinformatics resources; high-end activity screening technology; bioanalytical and bioprocess engineering facilities and expertise, nanoparticle-biocatalysts; high-quality protein crystallization and structural analysis facilities and experts in IP management for biotechnology. The companies involved in the project are market leaders in enzyme production and biocatalysis processes designed to efficiently deliver safer (pharmaceuticals) cheaper (agriculture) and biobased (biopolymers) products. They also have impressive track record in environmental clean-up technologies and are committed to promoting public understanding, awareness and dissemination of scientific research. The main emphasis will be focused on streamlining and shortening the pipelines for enzyme and bioactive compound discovery towards industrial applications through the establishing of marine enzyme collections with a high proportion of enzymes-allrounders. The project will also prioritize the identification of novel lead products and the delivery of improved prototypes for new biocatalytic processes.